EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Triple targeting of mutant EGFR L858R/T790M , COX-2, and 15-LOX: design and synthesis of novel quinazolinone tethered phenyl urea derivatives for anti-inflammatory and anticancer evaluation

Hend Kothayer iD, Samar Rezq iD, Ahmed S Abdelkhalek iD, Damian G Romero iD, Samar S Elbaramawi iD

Journal of Enzyme Inhibition and Medicinal Chemistry · 2023

DOI: 10.1080/14756366.2023.2199166 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Enzyme Inhibition and Medicinal Chemistry, 2023. Verfasst von Hend Kothayer und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt. Hauptthemen laut MEDLINE: ErbB Receptors, Lung Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, National Institutes of Health, National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We designed and synthesised novel quinazolinone tethered phenyl urea derivatives (6a-p) that triple target the double mutant EGFRL858R/T790M, COX-2, and 15-LOX. Compounds (6e, 6d, 6j, 6m, and 6n) not only had low micromolar IC50 inhibitory activities against the three targets, but they also showed good selectivity for COX-2 over COX-1 and for EGFRL858R/T790M over wild-type EGFR. Except for 6e and 6n, all of the tested compounds inhibited the NO production significantly more potently than celecoxib, diclofenac, and indomethacin. Compounds 6i and 6k reduced ROS levels more effectively than celecoxib and diclofenac. In terms of inhibiting TNF-α production, 6o-treated cells showed TNF-α level, which is ∼10 times lower than celecoxib. Furthermore, 6e and 6j had the highest anticancer activity against the breast cancer cell line BT-459 with growth inhibition percentages of 67.14 and 70.07%, respectively. Docking studies confirm their favoured binding affinity. The proposed compounds could be promising multi-targeted leads.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErbB ReceptorsLung NeoplasmsHumansCyclooxygenase 2QuinazolinonesCelecoxibDiclofenacTumor Necrosis Factor-alphaProtein Kinase InhibitorsMutationAnti-Inflammatory AgentsUreaStructure-Activity RelationshipMolecular Docking Simulation

Stichwörter der Autor:innen

Triple EGFR/COX-2/15-LOX inhibitorsanticancerin vitro anti-inflammatoryphenyl ureaquinazoline

Substanzen

ErbB ReceptorsCyclooxygenase 2QuinazolinonesCelecoxibDiclofenacTumor Necrosis Factor-alphaProtein Kinase InhibitorsAnti-Inflammatory AgentsUreaEGFR protein, human

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt.
  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt.
  • Department of Cell and Molecular Biology, University of Mississippi Medical Center, Jackson, MS, USA.
  • Mississippi Center of Excellence in Perinatal Research, University of Mississippi Medical Center, Jackson, MS, USA.
  • Women's Health Research Center, University of Mississippi Medical Center, Jackson, MS, USA.
  • Cardiovascular-Renal Research Center, University of Mississippi Medical Center, Jackson, MS, USA.

ORCID-Profile: Hend Kothayer, Samar Rezq, Ahmed S Abdelkhalek, Damian G Romero, Samar S Elbaramawi

Förderung

  • NIGMS NIH HHS
  • National Institutes of Health, National Institute of General Medical Sciences

Zitieren

APA

Kothayer, H., Rezq, S., Abdelkhalek, A. S., Romero, D. G., & Elbaramawi, S. S. (2023). Triple targeting of mutant EGFR L858R/T790M , COX-2, and 15-LOX: design and synthesis of novel quinazolinone tethered phenyl urea derivatives for anti-inflammatory and anticancer evaluation. Journal of Enzyme Inhibition and Medicinal Chemistry. https://doi.org/10.1080/14756366.2023.2199166

Vancouver

Kothayer H, Rezq S, Abdelkhalek AS, Romero DG, Elbaramawi SS. Triple targeting of mutant EGFR L858R/T790M , COX-2, and 15-LOX: design and synthesis of novel quinazolinone tethered phenyl urea derivatives for anti-inflammatory and anticancer evaluation. Journal of Enzyme Inhibition and Medicinal Chemistry. 2023. doi:10.1080/14756366.2023.2199166

BibTeX
@article{Kothayer2023,
  author = {Kothayer, Hend and Rezq, Samar and Abdelkhalek, Ahmed S and Romero, Damian G and Elbaramawi, Samar S},
  title = {Triple targeting of mutant EGFR L858R/T790M , COX-2, and 15-LOX: design and synthesis of novel quinazolinone tethered phenyl urea derivatives for anti-inflammatory and anticancer evaluation},
  journal = {Journal of Enzyme Inhibition and Medicinal Chemistry},
  year = {2023},
  doi = {10.1080/14756366.2023.2199166}
}
Kostenlos starten →